Evidence map›Paper›PMID 34252522›Full record

ArticleInternational journal of pharmaceutics2021

Development and preclinical evaluation of microneedle-assisted resveratrol loaded nanostructured lipid carriers for localized delivery to breast cancer therapy.

Shivaprasad Gadag, Reema Narayan, Archana S Nayak, Diana Catalina Ardila, Shilpa Sant, Yogendra Nayak, Sanjay Garg, Usha Y Nayak

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. 3D printed microneedles: revamping transdermal drug delivery systems.Drug delivery and translational research · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Shivaprasad GadagDepartment of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Reema NarayanDepartment of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Archana S NayakDepartment of Chemical Engineering, National Institute of Technology Karnataka, Surathkal, Mangalore, Karnataka, 575025, India.
Diana Catalina ArdilaDepartment of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA 15261, USA.
Shilpa SantDepartment of Pharmaceutical Sciences, School of Pharmacy, Pittsburgh, PA 15261, USA; Department of Bioengineering, Swanson School of Engineering, Pittsburgh, PA 15261, USA; McGowan Institute for Regenerative Medicine, Pittsburgh, PA 15261, USA; UPMC Hillman Cancer Center, Pittsburgh, PA 15261, USA.
Yogendra NayakDepartment of Pharmacology, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Sanjay GargUniSA: Clinical and Health Sciences, University of South Australia, Adelaide, SA 5000, Australia.
Usha Y NayakDepartment of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India. Electronic address: usha.nayak@manipal.edu.
Manipal Academy of Higher Education · INUniversity of Pittsburgh · USNational Institute of Technology Karnataka · INUniversity of South Australia · AU

Funding

Three-dimensional organoid models to study breast cancer progressionR37CA232209 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SANT, SHILPA · 2018 to 2024
$3.0M
NCI NIH HHS R37 CA232209
6 · The paper itself

Abstract

Resveratrol (RVT) is one of the potent anticancer phytochemicals which has shown promising potential for breast cancer therapy. However, its short half-life and low bioavailability is a major hurdle in its effective use. In this study, we have developed nanostructured lipid carriers (NLCs) of RVT to enable localized delivery of the drug to the breast tissues using microneedle arrays to improve effectiveness. The NLCs were optimized using the Design of Experiments approach and characterized for their particle size, polydispersity index, zeta potential and entrapment efficiency. The RVT-NLCs delivered using microneedle array 1200 showed a higher permeation of RVT across the skin with lower skin retention compared to pure RVT. Further, RVT-NLCs showed higher anticancer activity on MDA-MB-231 breast cancer cell lines and enhanced internalization compared to pure RVT. Moreover, the RVT-NLCs were found to inhibit the migration of MDA-MB-231 breast cancer cell lines. Preclinical studies in rats showed that RVT-NLCs delivered via microneedles demonstrated a remarkable increase in the C

Indexed as

NanostructuresNeoplasmsAnimalsDrug CarriersDrug Delivery SystemsLipidsParticle SizeRatsResveratrolDrug CarriersLipidsResveratrolBreast cancerMicroneedle arrayNanostructured lipid carrierResveratrolTransdermal drug delivery

Identifiers

PMID34252522
PMCPMC8429179
OpenAlexW3177518324

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.